135 related articles for article (PubMed ID: 38929802)
1. The Immunomodulatory Potential of Concurrent High-Dose Radiotherapy and Immune Checkpoint Inhibitor Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma: Initial Results.
Lo Greco MC; Marano G; Milazzotto R; Liardo RLE; Finocchiaro I; La Rocca M; Basile A; Foti PV; Palmucci S; David E; Pergolizzi S; Spatola C
J Pers Med; 2024 May; 14(6):. PubMed ID: 38929802
[TBL] [Abstract][Full Text] [Related]
2. Real-Life Study of the Benefit of Concomitant Radiotherapy with Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma (cSCC): A Retrospective Cohort Study.
Bailly-Caillé B; Kottler D; Morello R; Lecornu M; Kao W; Meyer E; Dompmartin A; L'Orphelin JM
Cancers (Basel); 2023 Jan; 15(2):. PubMed ID: 36672444
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Cemiplimab as Adjuvant or Neoadjuvant Therapy in the Treatment of Cutaneous Squamous Cell Carcinoma.
Hiller A; Oxford M; Kulkarni P; Fornadley J; Lo A; Sivik J; Drabick J; Vakharia K
Ann Plast Surg; 2024 Apr; 92(4S Suppl 2):S129-S131. PubMed ID: 38556660
[TBL] [Abstract][Full Text] [Related]
4. Previous radiotherapy increases the efficacy of cemiplimab in the treatment of locally advanced and metastatic cutaneous squamous cell carcinoma: a retrospective analysis.
Nardone V; Napolitano S; Gagliardi F; Esposito A; Caraglia F; Briatico G; Scharf C; Ronchi A; D'Onofrio I; D'Ippolito E; Russo A; Belfiore MP; Franco R; Argenziano G; Ciardiello F; Reginelli A; Cappabianca S; Troiani T
J Am Acad Dermatol; 2024 Jun; ():. PubMed ID: 38885840
[TBL] [Abstract][Full Text] [Related]
5. Real world data of cemiplimab in locally advanced and metastatic cutaneous squamous cell carcinoma.
Baggi A; Quaglino P; Rubatto M; Depenni R; Guida M; Ascierto PA; Trojaniello C; Queirolo P; Saponara M; Peris K; Spagnolo F; Bianchi L; De Galitiis F; Potenza MC; Proietti I; Marconcini R; Botticelli A; Barbieri V; Licitra L; Alfieri S; Ficorella C; Cortellini A; Fargnoli MC; Troiani T; Tondulli L; Bossi P
Eur J Cancer; 2021 Nov; 157():250-258. PubMed ID: 34536948
[TBL] [Abstract][Full Text] [Related]
6. Cemiplimab for advanced cutaneous squamous cell carcinoma in kidney transplant recipients.
Van Meerhaeghe T; Baurain JF; Bechter O; Orte Cano C; Del Marmol V; Devresse A; Doubel P; Hanssens M; Hellemans R; Lienard D; Rutten A; Sprangers B; Le Moine A; Aspeslagh S
Front Nephrol; 2022; 2():1041819. PubMed ID: 37675002
[TBL] [Abstract][Full Text] [Related]
7. First-line programmed death-1 inhibitor treatment for locoregionally advanced or metastatic cutaneous squamous cell carcinoma - A real-world experience from Israel.
Averbuch I; Salman S; Shtamper N; Doweck I; Popovtzer A; Markel G; Hendler D; Finkel I; Moore A; Fenig E; Taha T; Mhameed K; Kurman N; Billan S
Front Oncol; 2023; 13():1117804. PubMed ID: 36793605
[TBL] [Abstract][Full Text] [Related]
8. Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma: Real-World Experience in a Monographic Oncology Center.
Ríos-Viñuela E; Álvarez P; Lavernia J; Serra-Guillén C; Requena C; Bernia E; Diago A; Llombart B; Sanmartín O
Actas Dermosifiliogr; 2022 Jun; 113(6):T610-T615. PubMed ID: 35525283
[TBL] [Abstract][Full Text] [Related]
9. Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma: Real-World Experience in a Monographic Oncology Center.
Ríos-Viñuela E; Álvarez P; Lavernia J; Serra-Guillén C; Requena C; Bernia E; Diago A; Llombart B; Sanmartín O
Actas Dermosifiliogr; 2022 Jun; 113(6):610-615. PubMed ID: 35431057
[TBL] [Abstract][Full Text] [Related]
10. Response of advanced cutaneous squamous cell carcinoma to immunotherapy: case report.
Ashraf S; Alsharedi M
Stem Cell Investig; 2021; 8():19. PubMed ID: 34631872
[TBL] [Abstract][Full Text] [Related]
11. Cemiplimab for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma: Appropriate Patient Selection and Perspectives.
Mager L; Gardeen S; Carr DR; Shahwan KT
Clin Cosmet Investig Dermatol; 2023; 16():2135-2142. PubMed ID: 37581012
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint inhibitor therapy for advanced cutaneous squamous cell carcinoma in Australia: a retrospective real world cohort study.
McLean LS; Lim AM; Bressel M; Lee J; Ladwa R; Guminski AD; Hughes B; Bowyer S; Briscoe K; Harris S; Kukard C; Zielinski R; Alamgeer M; Carlino M; Mo J; Park JJ; Khattak MA; Day F; Rischin D
Med J Aust; 2024 Feb; 220(2):80-90. PubMed ID: 38212673
[TBL] [Abstract][Full Text] [Related]
13. PD-1 Inhibitors in Elderly and Immunocompromised Patients with Advanced or Metastatic Cutaneous Squamous Cell Carcinoma.
Yakobson A; Abu Jama A; Abu Saleh O; Michlin R; Shalata W
Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627069
[TBL] [Abstract][Full Text] [Related]
14. Promising Immune Treatment of Advanced Cutaneous Squamous Cell Carcinoma with Cemiplimab-Real-World Experience in the Global SARS-CoV-2 Pandemic.
Pabianek M; Lesiak A; Nejc D; Kuncman Ł; Narbutt J; Skibińska M; Ciążyńska M
Curr Oncol; 2022 Oct; 29(10):7794-7801. PubMed ID: 36290893
[TBL] [Abstract][Full Text] [Related]
15. Case Series: Cemiplimab and Nivolumab Immunotherapy as Promising Treatment in Advanced or Metastatic Cutaneous Squamous Cell Carcinoma.
Lai FY; Clarke R; Cooper P; Stokes J; Calvert P
Case Rep Oncol; 2023; 16(1):1156-1165. PubMed ID: 37900839
[TBL] [Abstract][Full Text] [Related]
16. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma.
Migden MR; Rischin D; Schmults CD; Guminski A; Hauschild A; Lewis KD; Chung CH; Hernandez-Aya L; Lim AM; Chang ALS; Rabinowits G; Thai AA; Dunn LA; Hughes BGM; Khushalani NI; Modi B; Schadendorf D; Gao B; Seebach F; Li S; Li J; Mathias M; Booth J; Mohan K; Stankevich E; Babiker HM; Brana I; Gil-Martin M; Homsi J; Johnson ML; Moreno V; Niu J; Owonikoko TK; Papadopoulos KP; Yancopoulos GD; Lowy I; Fury MG
N Engl J Med; 2018 Jul; 379(4):341-351. PubMed ID: 29863979
[TBL] [Abstract][Full Text] [Related]
17. Case Report: Autoimmune Pemphigus Vulgaris in a Patient Treated With Cemiplimab for Multiple Locally Advanced Cutaneous Squamous Cell Carcinoma.
Buquicchio R; Mastrandrea V; Strippoli S; Quaresmini D; Guida M; Filotico R
Front Oncol; 2021; 11():691980. PubMed ID: 34540666
[TBL] [Abstract][Full Text] [Related]
18. Identifying candidates for immunotherapy with cemiplimab to treat advanced cutaneous squamous cell carcinoma: an expert opinion.
Argenziano G; Fargnoli MC; Fantini F; Gattoni M; Gualdi G; Pastore F; Pellacani G; Quaglino P; Queirolo P; Troiani T
Ther Adv Med Oncol; 2022; 14():17588359211066272. PubMed ID: 35035534
[TBL] [Abstract][Full Text] [Related]
19. [Locally advanced and metastatic cutaneous squamous cell carcinoma treated with cemiplimab].
Vanhakendover L; Lebas E; Libon F; Wauters O; Dezfoulian B; Marchal N; Rorive A; Piret P; Quatresooz P; Jacquemin D; Nikkels AF
Rev Med Liege; 2019 Jul; 74(7-8):436-440. PubMed ID: 31373461
[TBL] [Abstract][Full Text] [Related]
20. Real-World Experience with Cemiplimab Treatment for Advanced Cutaneous Squamous Cell Carcinoma-A Retrospective Single-Center Study.
Kuzmanovszki D; Kiss N; Tóth B; Tóth V; Szakonyi J; Lőrincz K; Hársing J; Kuroli E; Imrédi E; Kerner T; Patyánik M; Wikonkál NM; Szabó Á; Brodszky V; Rencz F; Holló P
J Clin Med; 2023 Sep; 12(18):. PubMed ID: 37762907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]